Vanguard Group Inc Indaptus Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 256,265 shares of INDP stock, worth $676,539. This represents 0.0% of its overall portfolio holdings.
Number of Shares
256,265
Previous 256,265
-0.0%
Holding current value
$676,539
Previous $451,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding INDP
# of Institutions
18Shares Held
588KCall Options Held
0Put Options Held
0-
Investment House LLC Las Vegas, NV102KShares$270,4330.01% of portfolio
-
Geode Capital Management, LLC Boston, MA54.8KShares$144,5840.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$119,6870.02% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$116,5420.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny26.1KShares$68,9040.0% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $21.8M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...